Telesis Bio Inc (TBIO) USD0.0001

Sell:$0.30Buy:$0.30No change

Prices delayed by at least 15 minutes
Sell:$0.30
Buy:$0.30
Change:No change
Deal now
Prices delayed by at least 15 minutes
Sell:$0.30
Buy:$0.30
Change:No change
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.

Key people

Eric Esser
President, Chief Executive Officer, Director
William J. Kullback
Chief Financial Officer
Daniel G. Gibson
Chief Technology Officer
Franklin R. Witney
Non-Executive Independent Chairman of the Board
Steve Golub
Director
Sarah Hlavinka
Director
Michael Hodges
Director
Todd Krueger
Director
Click to see more

Key facts

  • EPIC
    TBIO
  • Location
    United States
  • Sector
    Technology
  • Industry
    Scientific & Technical Instr.
  • ISIN
    US1920032000
  • Market cap
    $532,750.00
  • Employees
    137
  • Shares in issue
    1.78m
  • Exchange
    Over The Counter
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.